***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: OBJECTIVE To observe the effect of birid triple viable on peptic ulcer patients with Helicobacter pylori(H.pylori ) infection . METHODS A total of 120 peptic ulcer patients with H.pylori infection was r and omly divided into 2 groups . The control group was treated with the triple therapy including Esomeprazole , Amoxicillin , and Furazolidone . The treatment group was treated with the same triple therapy plus birid triple viable .  The pH values of the gastric juice , bacterial culture of the gastric juice , the therapy-related side effects and the healing rate of ulcer and erosive were observed before the treatment and after a 14-day-treatment respectively . The (14)C-urea breath test((14)C-UBT ) was used to evaluate the H.pylori eradication rates 4 weeks after the treatment . RESULTS After the treatment , pH values of the gastric juice in both groups were significantly higher than those before the treatment ( P<0.05 ) . When pH values of the gastric juice ≥4 , the positive rate of bacterial culture in the treatment group was lower than that of the control group ( 80.0 % and 97.4 % respectively , P<0.05 ) . The rate of adverse effects in the treatment group was lower than that in the control group ( 11.7 % and 30 % respectively , P<0.05).After a 2-week treatment , the healing rate of ulcer and erosion was 80 % and 68.7 % in the treatment group , and 73.3 % and 40.7 % in the control group . The healing rate of ulcer had no significant difference in the 2 groups (P>0.05),while the healing rate of erosion in the treatment group was higher than that of the control group (P<0.05).The H.pylori eradication rates evaluated by per- protocol ( PP ) analysis in the treatment group was significantly higher than that of the control group ( 80.4 % and 62.4 % respectively , P<0.05 ) . CONCLUSION The combined use of birid triple viable and the triple therapy of H.pylori in peptic ulcer patients with H.pylori infection can reduce the bacteria of the gastric juice and therapy-related side effects . It can increase the H.pylori eradication rate and promote the healing of erosion OBJECTIVES : Helicobacter pylori is causally associated with gastritis and peptic ulcer diseases . Recent data ( meta- analysis ) have demonstrated that triple therapy with amoxicillin , clarithromycin , and a proton pump inhibitor has an eradication rate of only 74–76 % and new therapeutic protocol s may be necessary . The aim of this study was to examine whether adding bovine lactoferrin ( bLf ) and probiotics ( Pbs ) to the st and ard triple therapy for H. pylori infection could improve the eradication rate and reduce side effects . METHODS : H. pylori infection was diagnosed in 206 patients : in 107 based on an upper endoscopy exam and a rapid urease test , and in 99 by means of the H. pylori stool antigen-test and the C13 urea breath test ( C13 UBT ) . The patients were r and omized into two groups : 101 patients ( group A ) underwent st and ard triple eradication therapy ( esomeprazole , clarithromycin , amoxicillin ) , while 105 patients ( group B ) underwent a modified eradication therapy ( st and ard triple eradication therapy plus bLf and Pb ) . Successful eradication therapy was defined as a negative C13 UBT 8 wk after completion of the treatment . Results were evaluated by intention-to-treat ( ITT ) and per- protocol ( PP ) analysis . Data were evaluated and considered positive when P < 0.05 . RESULTS : At the end of the study 175/206 patients showed negative C13 UBT results . According to intention-to-treat analysis , the infection was eradicated in 73/101 patients from Group A and in 93/105 from Group B. PP analysis showed 73/96 patients from Group A and 93/101 from Group B to have been successfully treated . More patients from group A than from group B reported side effects from their treatment ( P < 0.05 ) . CONCLUSIONS : The results of our study suggest that the addition of bLf and Pbs could improve the st and ard eradication therapy for H. pylori infection — bLf serving to increase the eradication rate and Pbs to reduce the side effects of antibiotic therapy BACKGROUND Lactobacillus- and Bifidobacterium-containing yogurt ( AB-yogurt ) can suppress Helicobacter pylori . Improvement of the eradication rate by quadruple therapy of residual H. pylori after failed triple therapy is needed . OBJECTIVE We tested whether prior treatment with AB-yogurt improved the efficacy of quadruple therapy  in eradicating residual H. pylori after failed triple therapy . DESIGN One hundred thirty-eight patients in whom triple therapy failed were enrolled for a culture study of H. pylori to assess antimicrobial resistance . These patients were then r and omly assigned in equal numbers to either a yogurt-plus-quadruple therapy group or a quadruple therapy-only group . The patients received 1 wk of quadruple therapy with or without a 4-wk pretreatment with AB-yogurt ( 400 mL/d ) . In the yogurt-plus-quadruple group , excessive delta(13)CO(2)/mL values of the (13)C-urea breath test were collected before and every 2 wk during the 4-wk ingestion of yogurt . For both groups , a (13)C-urea breath test was conducted > or = 6 wk after the quadruple therapy to assess the outcome of residual H. pylori eradication . RESULTS For the patients in the yogurt-plus-quadruple therapy group infected with either antibiotic-sensitive or -resistant H. pylori , the excessive delta(13)CO(2)/mL values of the (13)C-urea breath test were significantly decreased after the 4-wk ingestion of AB-yogurt ( P < 0.0001 ) . The yogurt-plus-quadruple therapy group had a higher H. pylori eradication rate than did the quadruple therapy-only group ( intention-to-treat analysis : 85 % compared with 71.1 % , P < 0.05 ; per- protocol analysis : 90.8 % compared with 76.6 % , P < 0.05 ) . CONCLUSION A 4-wk pretreatment with AB-yogurt can decrease H. pylori loads despite antimicrobial resistance , thus improving the efficacy of quadruple therapy  in eradicating residual H. pylori BACKGROUND & AIMS Probiotics is an emerging therapeutic agent which may alleviate the symptoms of constipation . We evaluated the effectiveness of microbial cell preparation ( Hexbio ( ® ) ) containing fructooligosaccharide , Bifidobacterium and Lactobacillus in improving stool frequency and symptoms of chronic constipation . METHODS A total of 120 constipated adults diagnosed using Rome III criteria were r and omized and given either microbial cell preparation or placebo to be consumed twice daily . Follow-up was done after a 7-day intervention based on a question naire which includes an assessment of symptom profile and a stool diary . RESULTS During the intervention period , the stool frequency was higher ( p = 0.001 ) in the treatment group . Subjects experienced less straining ( p = 0.001 ) and sensation of incomplete evacuation ( p < 0.001 ) , as well as improved stool consistency ( p < 0.001 ) compared to the placebo group . While a higher proportion of subjects in the treatment group had a reduction in anorectal blockage sensation and having to defecate by manual maneuvers , the differences were not statistically significant . CONCLUSION The results suggest that microbial cell preparation is effective in improving stool frequency and stool consistency . Furthermore , it could reduce the symptoms of straining and sensation of incomplete evacuation in adults with chronic functional constipation . MREC REG NO 866.59 ( IRB , UMMC , Malaysia ) Background Recent data suggest a role for the intestinal microbiota in the pathogenesis of functional bowel disorders ( FBDs ) . Probiotic studies in FBDs generated inconsistent results suggesting a strain-specific and product-specific effect . Aim To investigate the clinical efficacy of Lactobacillus acidophilus NCFM ( L-NCFM ) and Bifidobacterium lactis Bi-07 ( B-LBi07 ) in nonconstipation FBDs . Methods A double-blind , placebo-control clinical trial of the probiotic bacterias L-NCFM and B-LBi07 twice a day ( 2 × 1011CFU/d ) versus placebo over 8 weeks . Primary endpoints were global relief of gastrointestinal symptoms and satisfaction with treatment . Secondary endpoints were change in symptoms severity , well-being , and quality of life . Microbiological effect was assessed by quantitative real time polymerase chain reaction on fecal sample s. Results Sixty patients ( probiotic , n=31 ; placebo , n=29 ) , 72 % females , 84 % whites , mean age 37 years . Abdominal bloating improved in the probiotics compared with the placebo group at 4 weeks ( 4.10 vs 6.17 , P=0.009 ; change in bloating severity P=0.02 ) and 8 weeks ( 4.26 vs 5.84 , P=0.06 ; change in bloating severity P<0.01 ) . Analyses on the irritable bowel syndrome subgroup ( n=33 ) showed similar results . Conclusions L-NCFM and B-LBi07 twice a day improve symptoms of bloating in patients with FBDs . These data supports the role of intestinal bacteria in the pathophysiology of FBD and the role for probiotic bacteria in the management of these disorders OBJECTIVES : Several studies show that probiotics may prevent side effects during therapy against Helicobacter pylori ( H. pylori ) . Other reports indicate competitive interaction between some probiotics and H. pylori . We compared efficacy of two different probiotics and one probiotic combination with placebo for preventing anti-H. pylori therapy-related side effects and for improving the eradication rate . METHODS : A total of 85 H. pylori positive , asymptomatic patients were r and omized in four groups to receive probiotic or placebo both during and for 7 days after a 1-wk triple therapy scheme ( rabeprazole 20 mg b.i.d . , clarithromycin 500 mg b.i.d . , and tinidazole 500 mg b.i.d . ) . Group I ( n = 21 ) received Lactobacillus GG ; group II ( n = 22 ) , Saccharomyces boulardii ; group III ( n = 21 ) , a combination of Lactobacillus spp . and biphidobacteria ; and group IV ( n = 21 ) , placebo . Subjects filled in weekly symptom question naires for 4 wk . Blinded investigators collected and analyzed data . H. pylori status was rechecked after 5–7 wk . RESULTS : Side effects occurred mainly during the eradication week . None of them caused therapy discontinuation . In all probiotic-supplemented groups , there was a significantly lower incidence of diarrhea and taste disturbance during the eradication week with respect to the placebo group . Overall assessment of tolerability was significantly better in the actively treated patients than in the placebo group . No differences in the incidence of side effects between the probiotic groups were observed . The H. pylori eradication rate was almost identical between the probiotic and placebo groups . CONCLUSIONS : All the probiotics used were superior to placebo for side effect prevention , but were not associated with better compliance with antibiotic therapy . The effect of probiotic supplementation on side effects during anti-H. pylori regimens seemed to be independent of the probiotic species used Background To evaluate whether the addition of a probiotic could improve  Helicobacter pylori ( H.P. ) eradication rates and reduce the side effects of treatment in children . Methods Between July 2008 and July 2011 all patients with a clinical , laboratory and endoscopic diagnosis of H.P. positive gastritis referred to our Unit were included in the study . Patients suffering from allergy to any of drugs used in the study , with previous attempts to eradicate H.P. and those who received antibiotics , PPIs or probiotics within 4 weeks were excluded from the present study . Patients were r and omized into two therapy regimens ( group A and B ) : both groups received st and ard triple treatment ( omeprazole , amoxicillin and clarithromycin ) while only group B patients were also given a probiotic ( Probinul - Cadigroup ) . Patients compliance was evaluated at the end of the treatment . Successful eradication was defined as a negative 13 C-urea breath test ( C13-ubt ) result four weeks after therapy discontinuation . Results A total of 68 histopathologically proven H.P.-infection children ( 32 male and 36 females ) were included in the 
    Output:
    
The use of probiotics plus st and ard therapy was associated with an increase in the H. pylori eradication rate , and a reduction in adverse events result ing from treatment in the general population .
However , this therapy did not improve patient compliance